Tuberculosis News and Research

Latest Tuberculosis News and Research

Op-Eds: HIV travel ban; improving sanitation; counterfeit drugs

A "blot" on U.S. HIV/AIDS leadership "ended last month when President [Barack] Obama lifted the prohibition" that kept HIV-positive foreigners from visiting the U.S. or seeking residency, according to a Washington Post editorial. "The process for eliminating the travel ban started under President George W. Bush in July 2008, when he signed legislation that repealed the original statute."

19 Nov 2009

New online tool launched to encourage donations and fight global hunger

Mercy Corps is challenging Americans to put the "giving" back in Thanksgiving by matching the amount they spend on a meal this Thanksgiving Day with a donation that fights global hunger.

19 Nov 2009

Opinions: Fighting TB; currency transaction tax

Though tuberculosis "is one of the world's leading killers … few citizens, scientists and policymakers are demanding more attention to TB research, treatment and prevention. … It's time to bring TB research into the 21st century," Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, writes in an MSNBC opinion piece.

19 Nov 2009

Ionian Technologies receives supplemental funding from the Gates Foundation

Ionian Technologies, Inc., will continue its efforts to develop a rapid point-of-care diagnostics platform for use in the developing world with supplemental funding from the Bill & Melinda Gates Foundation. This grant from the Foundation will extend the total commitment to this program, which was initiated in November 2008, to $3 million over two years.

18 Nov 2009

MSF's volunteer physicians receive free access to Elsevier's electronic CDS tool

The physicians of the world renowned Doctors Without Borders/Medecins Sans Frontieres (MSF), which won the Nobel Peace Prize in 1999, will receive free access to MD Consult (www.mdconsult.com), Elsevier's premier electronic clinical decision support (CDS) tool, as the result of a special new Elsevier campaign.

18 Nov 2009

Regulatory agencies offer marketing approval for new products to treat neglected diseases

New products to treat neglected diseases have received marketing approval from regulatory agencies at a steadily increasing rate in recent years as R&D funding for those diseases has increased, according to a recently completed study by the Tufts Center for the Study of Drug Development.

18 Nov 2009

Global Alliance for Chronic Diseases announces targets

The Global Alliance for Chronic Diseases (GACD) on Monday outlined plans "to invest tens of millions of dollars in heart and lung disease studies in a battle against a global epidemic of chronic disease," over five years, Reuters reports.

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

Economic crisis impacts health department capacity to address rising STD rates

Amid the mounting toll of budget cuts across the country, a new study from the National Coalition of STD Directors (NCSD) shows just how much an impact the economic crisis is having on sexually transmitted disease (STD) programs and in turn, having more broadly on public health infrastructure.

17 Nov 2009

Sequella broadens the licensed therapeutic indications of its SQ109 lead drug candidate

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.

16 Nov 2009

New faces of HIV/AIDS: A report

World AIDS Day 2009 will be marked with both grim and hopeful data: more than 25 million people have died of AIDS worldwide since 1981; 33 million are living with HIV/AIDS. While potent, effective medications have changed an HIV diagnosis from death sentence to manageable chronic illness in resource rich countries, global rates of infection still outstrip prevention and treatment capacity.

16 Nov 2009

Some combination drug therapies are counter-productive

Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.

16 Nov 2009

TIME examines efforts to combat malaria resistance along Thai-Cambodia border

TIME reports on evidence along the Thai-Cambodia border that the malaria parasite is gaining resistance to artemisinin - "the only remaining effective drug in the world's arsenal against malaria's most deadly strain."

16 Nov 2009

Recent releases in Global Health

As a follow-up to a survey conducted in May 2009, this poll examines Americans' attitudes toward U.S. global health investments and priorities.

16 Nov 2009

Global Fund approves $2.4B for ninth round grants

During its recent board meeting in Addis Ababa, Ethiopia, the Global Fund to Fight AIDS, Tuberculosis and Malaria approved $2.4 billion for the three diseases, PlusNews reports.

16 Nov 2009

Health policy research round up - Medicare and Massachusetts

Robert Wood Johnson Foundation: The Secrets of Massachusetts' Success - "By the summer of 2008, less than two years after Massachusetts' health reform law became effective, only 2.6 percent of state residents were uninsured—the lowest proportion ever recorded for any state." This study by the RWJF-funded State Health Access Reform Evaluation (SHARE) initiative "explains how national reforms can use similar methods to avoid the pitfalls that have plagued other coverage expansions."

13 Nov 2009

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Emergent BioSolutions Inc. announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.

13 Nov 2009

Today's opinions and editorials

"Traditional" infectious diseases — those, like flu and tuberculosis, that are caused by viruses or bacteria — are not the only aspects of health that can spread from one person to another. Taking up smoking is contagious; so is quitting. Obesity is contagious. So is happiness (Olivia Judson, 11/10).

12 Nov 2009

Drug companies collaborate with nonprofit organizations to fight "neglected" diseases in the developing world

Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. Those hard-to-treat diseases include malaria, tuberculosis, dengue fever, and other conditions. That's the topic of the cover story scheduled for the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

12 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009